Inactive Instrument

Biotoscana Investments S.A.

GBIO33

BRGBIOBDR008

Tranche Update on Biotoscana Investments S.A.'s Equity Buyback Plan announced on August 14, 2018.

November 13, 2018 at 04:30 pm IST

From July 1, 2018 to September 30, 2018, the company has repurchased 1,346,300 shares, representing 1.31% for BRL 14.12 million. With this, the company has completed the repurchase of 1,346,300 shares, representing 1.31% for BRL 14.12 million under the buyback announced on August 14, 2018.

Latest news about Biotoscana Investments S.A.

Biotoscana Investments S.A.(BOVESPA:GBIO33) dropped from S&P Global BMI Index	20/20/20	CI
1178991 Canada Inc. completed the acquisition of the remaining 48.8% stake in Biotoscana Investments S.A. approximately BRL 540 million.	14/20/14	CI
Biotoscana Investments S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2020	13/20/13	CI
Biotoscana Investments S.A. Reports Earnings Results for the First Quarter Ended March 31, 2020	26/20/26	CI
Tranche Update on Biotoscana Investments S.A.'s Equity Buyback Plan announced on August 14, 2018.	31/20/31	CI
Biotoscana Investments S.A. Reports Earnings Results for the Full Year Ended December 31, 2019	31/20/31	CI
Knight Therapeutics Inc. announced Unified Tender Offer to acquire remaining 48.8% stake in Biotoscana Investments S.A. for approximately BRL 450 million.	20/19/20	CI
Knight Therapeutics Inc. completed the acquisition of 51.21% stake in Biotoscana Investments S.A. from Advent Cartagena S.a r.l., Essex Woodlands Health Ventures VIII, L.P., Essex Woodlands Health Ventures VIII-A, L.P. and Essex Woodlands Health Ventures VIII-B, L.P. managed by Essex Woodlands Management, Inc., MAZAL INVESTMENT VENTURES LTD., Robert Friedlander and Roberto Guttman.	29/19/29	CI
Biotoscana Investments S.A. Reports Earnings Results for the Third Quarter Ended September 30, 2019	12/19/12	CI
Biotoscana Investments S.A.‘s Equity Buyback announced on August 14, 2018, has expired with 1,346,300 shares, representing 1.31% for BRL 14.12 million.	31/19/31	CI
BIOTOSCANA INVESTMENTS S.A. Announces Change in Management	29/19/29	CI
Canada's Knight Therapeutics to acquire Biotoscana control by Nov 29: filing	29/19/29	RE
Biotoscana Investments S A : Knight Therapeutics to purchase Biotoscana in $281 million deal	21/19/21	RE
Knight Therapeutics Inc. entered into an agreement to acquire 51.21% stake in Biotoscana Investments S.A. from Advent Cartagena S.a r.l., Essex Woodlands Health Ventures VIII, L.P., Essex Woodlands Health Ventures VIII-A, L.P. and Essex Woodlands Health Ventures VIII-B, L.P. managed by Essex Woodlands Management, Inc., MAZAL INVESTMENT VENTURES LTD., Robert Friedlander and Roberto Guttman for approximately BRL 600 million.	21/19/21	CI
Biotoscana Confirms Divestiture Negotiations	10/19/10	CI
Biotoscana Investments S A : Knight Terapeutics and Eurofarma eye Biotoscana	07/19/07	RE
Biotoscana Investments S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2019	13/19/13	CI
Tranche Update on Biotoscana Investments S.A.'s Equity Buyback Plan announced on August 14, 2018.	13/19/13	CI
EMS Is Reportedly Interested In Biotoscana	18/19/18	CI
Biotoscana Investments S.A. Reports Earnings Results for the First Quarter Ended March 31, 2019	13/19/13	CI
Tranche Update on Biotoscana Investments S.A.'s Equity Buyback Plan announced on August 14, 2018.	13/19/13	CI
Biotoscana Investments S.A. Reports Earnings Results for the Full Year Ended December 31, 2018	22/19/22	CI
Tranche Update on Biotoscana Investments S.A.'s Equity Buyback Plan announced on August 14, 2018.	22/19/22	CI
Tranche Update on Biotoscana Investments S.A.'s Equity Buyback Plan announced on August 14, 2018.	13/18/13	CI
Biotoscana Investments S.A. Announces Earnings Results for the Third Quarter of 2018	13/18/13	CI

Chart Biotoscana Investments S.A.

Duration

Period

More charts

Company Profile

Biotoscana Investments SA is a Luxembourg-based company engaged in the healthcare industry. The Company develops, manufactures and distributes pharmaceutical products. The Company offers drugs for the treatment of infectious and rare diseases, oncology, onco-hematology, special treatments and immunology, among others. Its product development pipeline is divided into two business models: partnership product development, which is focused on building relationships to license and commercialize products that are new to Latin America, and internal product development, which is focused on studying, designing, formulating and manufacturing branded generic products. Apart from the Luxembourg, the Company operates worldwide in a number of countries, including Peru, Argentina and Ecuador, among others.

Sector

Pharmaceuticals

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
KYOWA KIRIN CO. LTD.	+10.23%	9.11B
SK BIOPHARMACEUTICALS CO., LTD.	-10.76%	5.21B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+51.58%	4.83B
YUHAN CORPORATION	+12.50%	4.09B
BETTA PHARMACEUTICALS CO., LTD.	-20.70%	2.35B
INDIVIOR PLC	+12.83%	2.32B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+19.51%	2.27B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.65%	2.19B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals